Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Guidelines often Based on Weak Evidence

Will Boggs MD  |  

NEW YORK (Reuters Health)—Most recent clinical practice guidelines (CPGs) from the American College of Rheumatology (ACR) are based on expert opinion and lack A-level evidence in support of their recommendations, researchers report. “I’d like to highlight not just for providers but also for patients and policymakers that, even though we in the United States are…

Obesity’s Effects on Inflammatory Markers in Patients with RA

Arthritis Care & Research  |  

New research has examined the effect of obesity on inflammatory markers, specifically C-reactive protein (CRP) level and erythrocyte sedimentation rate, in patients with rheumatoid arthritis (RA). Researchers found higher BMIs were associated with higher CRP levels in women both with and without RA, suggesting the phenomenon is related to adiposity and not an indication of disease activity. For men with RA, low BMI was associated with higher CRP levels, which proved to be RA-specific but not a direct causal effect of adiposity…

SIRT1: A Therapeutic Target for Osteoporosis?

  |  

New research has found the sirtuin family of proteins may be a positive regulator of bone mass. In the study, pharmacological activation of SIRT1 in mice resulted in increased bone mass, suggesting the pharmacological activation of SIRT1 may protect against osteoporosis…

Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More

Angus Worthing, MD, FACP, FACR   |  

Greetings, advocates! This month’s Washington update covers how Congress’s tax proposals affect rheumatology, the ACR’s plan to fight Medicare’s adjustments to Part B drug costs in MIPS, the good news of Medicare’s new individualized biosimilar reimbursement, advances in the rheumatology-specific Alternative Payment Model and developments in Congress’s awareness about the perilous pharmacy benefit manager system….

Year in Review: Expert Covers 2017’s Key Clinical Findings

  |  

In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs

Deena Beasley  |  

(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…

Biosimilars Great Debate: To Switch or Not?

  |  

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…